Header

UZH-Logo

Maintenance Infos

Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus


Heijerman, H; Westerman, E; Conway, S; Touw, D; Döring, G (2009). Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. Journal of Cystic Fibrosis, 8(5):295-315.

Abstract

In cystic fibrosis inhalation of drugs for the treatment of CF related lung disease has been proven to be highly effective. Consequently, an increasing number of drugs and devices have been developed for CF lung disease or are currently under development. In this European consensus document we review the current status of inhaled medication in CF, including the mechanisms of action of the various drugs, their modes of administration and indications, their effects on lung function, exacerbation rates, survival and quality of life, as well as side effects. Specifically we address antibiotics, mucolytics/mucous mobilizers, anti-inflammatory drugs, bronchodilators and combinations of solutions. Additionally, we review the current knowledge on devices for inhalation therapy with regard to optimal particle sizes and characteristics of wet nebulisers, dry powder and metered dose inhalers. Finally, we address the subject of testing new devices before market introduction.

Abstract

In cystic fibrosis inhalation of drugs for the treatment of CF related lung disease has been proven to be highly effective. Consequently, an increasing number of drugs and devices have been developed for CF lung disease or are currently under development. In this European consensus document we review the current status of inhaled medication in CF, including the mechanisms of action of the various drugs, their modes of administration and indications, their effects on lung function, exacerbation rates, survival and quality of life, as well as side effects. Specifically we address antibiotics, mucolytics/mucous mobilizers, anti-inflammatory drugs, bronchodilators and combinations of solutions. Additionally, we review the current knowledge on devices for inhalation therapy with regard to optimal particle sizes and characteristics of wet nebulisers, dry powder and metered dose inhalers. Finally, we address the subject of testing new devices before market introduction.

Statistics

Citations

118 citations in Web of Science®
139 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

1 download since deposited on 17 Feb 2010
0 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Children's Hospital Zurich > Medical Clinic
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2009
Deposited On:17 Feb 2010 12:35
Last Modified:05 Apr 2016 13:56
Publisher:Elsevier
ISSN:1569-1993
Publisher DOI:https://doi.org/10.1016/j.jcf.2009.04.005
PubMed ID:19559658

Download